文献速递膀胱癌与上尿路尿路上皮癌

帕博利珠单抗膀胱内递送首次人体试验:在卡介苗无应答膀胱癌中识别免疫激活

First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin.
PubMed 文献 · Eur Urol · 2022-08-23

一项3+3 1期试验评估膀胱内帕博利珠单抗联合卡介苗治疗卡介苗无应答的非肌层浸润性膀胱癌的安全性和抗肿瘤活性,9例患者完成治疗,最大耐受剂量未达到,报告1例剂量限制性毒性(2级腹泻)和1例死亡(肌无力,被认为可能与治疗相关),6个月和1年无复发率分别为67%和22%。

要点

  • 膀胱内帕博利珠单抗联合卡介苗在卡介苗无应答NMIBC中安全、可行并能激发强烈免疫反应。
  • 最大耐受剂量未达到,报告1例剂量限制性毒性(2级腹泻)和1例可能与治疗相关的死亡(肌无力)。
  • 6个月和1年无复发率分别为67%(95%CI 42-100%)和22%(95%CI 6.5-75%)。

核心结论

  • 膀胱内帕博利珠单抗安全、可行,并能在临床环境中激发强烈的免疫反应,应进一步研究。
  • 直接向膀胱内应用帕博利珠单抗是卡介苗无应答非肌层浸润性膀胱癌的一种有前景的替代方案,应进一步研究。

研究设计与样本

  • 3+3 1期试验(NCT02808143),纳入卡介苗无应答的非肌层浸润性膀胱癌患者,评估膀胱内帕博利珠单抗联合卡介苗。
  • 9例患者完成治疗。

主要发现

  • 中位随访35个月,为试验结束时仍存活的5例患者的数据。
  • 1-2级泌尿系统症状常见。
  • 最大耐受剂量未达到;在唯一达到52周无复发的患者中报告1例剂量限制性毒性(2级腹泻)。
  • 发生1例死亡,死于肌无力,被认为可能与治疗相关。
  • 6个月无复发率为67%(95%CI 42-100%),1年无复发率为22%(95%CI 6.5-75%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验因COVID-19大流行而关闭。
  • 最大耐受剂量未达到。
  • 报告1例剂量限制性毒性(2级腹泻)和1例可能与治疗相关的死亡(肌无力)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intravenous immune checkpoint inhibition is an effective anticancer strategy for bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) but may be associated with greater systemic toxicity compared with localized therapies. OBJECTIVE: We assessed the safety and antitumor activity of intravesical pembrolizumab combined with BCG. DESIGN, SETTING, AND PARTICIPANTS: A 3 + 3 phase 1 trial of pembrolizumab + BCG was conducted in patients with BCG-unresponsive NMIBC (NCT02808143). INTERVENTION: Pembrolizumab was given intravesically (1-5 mg/kg for 2 h) beginning 2 weeks prior to BCG induction until recurrence. Urine profiling during treatment and spatial transcriptomic profiling of pre- and post-treatment tumors were conducted to identify biomarkers that correlated with response. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Safety and tolerability of immune checkpoint inhibition were assessed, and Kaplan-Meier survival analysis was performed. RESULTS AND LIMITATIONS: Nine patients completed therapy. Median follow-up was 35 months for five patients still alive at the end of the trial. The trial was closed due to the COVID-19 pandemic. Grade 1-2 urinary symptoms were common. The maximum tolerated dose was not reached; however, one dose-limiting toxicity was reported (grade 2 diarrhea) in the only patient who reached 52 weeks without recurrence. One death occurred from myasthenia gravis that was deemed potentially related to treatment. The 6-mo and 1-yr recurrence-free rates were 67% (95% confidence interval [CI]: 42-100%) and 22% (95% CI: 6.5-75%), respectively. Pembrolizumab was detected in the urine and not in blood. CD4+ T cells were significantly increased in the urine after treatment, and a transcriptomic analysis identified decreased expression of T-cell exhaustion markers in late recurrences. CONCLUSIONS: We demonstrate that intravesical pembrolizumab is safe, feasible, and capable of eliciting strong immune responses in a clinical setting and should be investigated further. PATIENT SUMMARY: Direct application of pembrolizumab to the bladder is a promising alternative for non-muscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin and should be investigated further.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Meghani K, Cooley LF, Choy B, et al. First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin. Eur Urol. 2022. PMID: 36008193. doi:10.1016/j.eururo.2022.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。